Predicts risk of advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). The BARD score uses three simple clinical parameters (BMI, AST/ALT ratio, and diabetes) to identify patients at low risk of advanced fibrosis who may not require liver biopsy.
Awaiting Clinical Input
Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.
The BARD Score for NAFLD Fibrosis is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hepatology.
Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.
Low risk of advanced fibrosis
High risk of advanced fibrosis
Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.
Open in Web AppClinical Decision Support (CDS) Notice & Legal Disclaimer
This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.